Navigation Links
Reportlinker Adds Point of Care Diagnostic Testing World Markets
Date:3/29/2011

NEW YORK, March 29, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Point of Care Diagnostic Testing World Markets

http://www.reportlinker.com/p089474/Point-of-Care-Diagnostic-Testing-World-Markets.html

Point of care testing (POCT) enables rapid diagnostic tests to be performed while the patient is at the point of care facility where results can be obtained immediately, rather than waiting hours or even days for outside lab results to arrive. Point of care testing covers: blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing, rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, food pathogens screening, hemoglobin diagnostics, infectious disease testing and cholesterol screening. This TriMark Publications report describes latest developments in the point of care testing market segment. It examines clinical instruments, devices and reagents and supplies as utilized in near-patient environments like hospital emergency rooms, critical care units, clinics and doctor's offices. The study defines the dollar volume of point of care sales and makes five year projections--both in the U.S. and worldwide--including Europe, Asia and Latin America. It also examines in detail the point of care sector for 25 individual country markets. A detailed summary of all important instruments in each clinical market is provided with emphasis on newly introduced products. Moreover, parallel areas where rapid detection is important using hand-held devices such as rapid detection of food pathogens and infectious diseases (MRSA, herpes simplex, avian flu, West Nile virus and typhoid) are discussed. Growth moderators and developing trends in point of care applications, as well as technology platform innovations and connectivity questions are examined in detail. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the point of care market in the U.S. and worldwide. Each company is discussed in depth, with a section on its history, product lines, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market data are also included.

TABLE OF CONTENTS

1. Overview 14

1.1 About this Report 14

1.2 Scope of the Report 15

1.3 Objectives 16

1.4 Methodology 16

1.5 Executive Summary 17

2. Overview of Diagnostic Testing Point of Care 21

2.1 Point of Care Testing Sites 21

2.2 Point of Care Market Structure 22

2.3 New Directions in Clinical IVD Testing 22

3. POCT and Rapid Testing Market Analysis: Size, Background Analysis, Growth,

Share and Competitors 25

3.1 Global POCT Market 31

3.2 U.S. POCT Market 34

3.3 European POCT Market 37

3.3.1 German POCT Diagnostic Market 43

3.3.2 U.K. POCT Diagnostic Market 45

3.3.2.1 U.K. POCT Market Statistics 45

3.3.2.2 U.K. Competitive Analysis 47

3.3.2.3 U.K. Market Access 48

3.3.3 French POCT Diagnostic Market 48

3.3.4 Italian POCT Diagnostic Market 49

3.3.5 Spanish POCT Diagnostic Market 51

3.3.6 Scandinavian POCT Diagnostic Market 52

3.3.7 Swedish POCT Diagnostic Market 53

3.3.8 Finnish POCT Diagnostic Market 54

3.3.9 Norwegian POCT Diagnostic Market 55

3.3.10 Swiss POCT Diagnostic Market 56

3.3.11 Dutch POCT Diagnostic Market 57

3.3.12 Belgian POCT Diagnostic Market 58

3.3.13 Portuguese POCT Diagnostic Market 59

3.3.14 Austrian POCT Diagnostic Market 60

3.3.15 Greek POCT Diagnostic Market 61

3.3.16 Polish POCT Diagnostic Market 62

3.3.17 Czech Republic POCT Diagnostic Market 63

3.3.18 Turkish POCT Diagnostic Market 64

3.4 Asian POCT Markets 64

3.4.1 Japanese POCT Diagnostic Market 64

3.4.2 Indian POCT Diagnostic Market 66

3.4.3 Chinese POCT Diagnostic Market 71

3.5 Rest of the World POCT Market 81

3.5.1 Canadian POCT Diagnostic Market 82

3.5.2 Brazilian POCT Diagnostic Market 82

3.5.3 Australian POCT Diagnostic Market 83

3.6 Overview of Asian Healthcare Market 83

3.6.1 Singapore 85

3.6.2 Malaysia 85

3.6.3 Thailand 86

3.6.4 Indonesia 86

3.6.5 Philippines 86

3.6.6 South Korea 87

3.6.7 Taiwan 87

4. POCT Individual Markets 88

4.1 Glucose Testing 88

4.2 POCT Individual Market Sectors, Size, Growth Rates and Competitors 89

4.2.1 World Market Revenue and Forecasts 89

4.2.2 Professional Glucose Testing Market for POCT U.S. Revenue and Forecasts

during

2001-2012 90

4.2.3 European Market 91

4.2.4 Market Share 91

4.2.5 Alternate Glucose Monitoring Products 92

4.2.6 HbA1c POCT 93

4.2.7 Market Challenges and Strategic Recommendations 94

4.2.7.1 Market Drivers and Restraints 94

4.2.7.1.1 Market Drivers 94

4.2.7.1.2 Market Restraints 94

4.2.7.2 Point of Care Glucose Testing Assay Market and Technology Trends 95

4.2.7.2.1 Point of Care Glucose Testing Assay Market Trends 95

4.2.7.2.2 Point of Care Glucose Testing Assay Technology Trends 95

4.2.7.2.3 Point of Care Glucose Testing Assay Strategic Recommendations 95

4.3 Blood Gas and Electrolytes 96

4.3.1 Whole Blood Lactate 99

4.4 Rapid Coagulation Tests 99

4.4.1 World POCT Coagulation Market 102

4.4.2 U.S. Coagulation Market 102

4.4.3 European Coagulation Market 106

4.4.4 Trends in POCT Coagulation Testing 106

4.4.4.1 Self-testing Coagulation Market 106

4.4.4.2 D-Dimer Testing 107

4.4.5 Point of Care Coagulation Testing Assay Market and Technology Trends 107

4.4.5.1 Point of Care Coagulation Testing Assay Market Trends 107

4.4.5.2 Point of Care Coagulation Testing Assay Technology Trends 108

4.4.5.3 Point of Care Coagulation Testing Assay Strategic Recommendations 108

4.5 Rapid Cardiac Markers 109

4.5.1 U.S. Market 109

4.5.2 European Market 111

4.5.3 Market Drivers and Restraints 113

4.5.3.1 Market Drivers 113

4.5.3.2 Market Restraints 113

4.5.4 Point of Care Cardiac Marker Testing Assay Market and Technology Trends

113

4.5.4.1 Point of Care Cardiac Marker Testing Assay Market Trends 113

4.5.4.2 Point of Care Cardiac Marker Testing Assay Technology Trends 114

4.5.4.3 Point of Care Cardiac Marker Testing Assay Strategic Recommendations 114

4.6 Drugs of Abuse Screening Testing 114

4.6.1 Acetaminophen 121

4.6.2 Tricyclic Antidepressants (TCAs) 122

4.6.3 Other Toxic Drugs 122

4.6.4 Drug Testing Selectivity 122

4.6.5 Methaqualone and Phencyclidine (PCP) 123

4.6.6 Tetrahydrocannabinol 123

4.6.7 Drug Panels by Toxidromes 123

4.6.8 Alcohol Testing 123

4.7 Urine Strips 124

4.8 Pregnancy Tests 127

4.9 Fecal Occult Blood 128

4.10 Hemoglobin Testing 129

4.11 Miscellaneous Rapid Tests 130

4.11.1 Estriol 130

4.11.2 Fetal Fibronectin (fFN) 131

4.11.3 H. pylori 131

4.11.4 Vaginal pH and Vaginitis 131

4.11.5 Bladder Cancer 132

4.11.6 Fetal Status 133

4.11.7 Heparin-induced Thrombocytopenia 133

4.12 Human Immunodeficiency Virus (HIV) 133

4.13 Cholesterol 140

4.14 Infectious Disease 141

4.14.1 Clostridium difficile 141

4.14.2 Giardia 142

4.14.3 Salmonella and Campylobacter 143

4.14.4 Malaria Testing 143

4.14.5 Influenza Testing 144

4.14.6 Strep Testing 148

4.14.7 Chlamydia 149

4.14.8 Mononucleosis 150

4.14.9 Rubella 150

4.14.10 Methicillin-resistant Staphylococcus aureus (MRSA) 151

4.14.11 Hepatitis 156

4.14.12 Gonorrhea 158

4.14.13 Tuberculosis (TB) 158

4.14.14 Herpes Simplex Virus Type-2 160

4.14.15 Legionella 160

4.14.16 RSV 161

4.14.16.1 Market Drivers and Restraints 163

4.14.16.1.1 Market Drivers 163

4.14.16.1.2 Market Restraints 163

4.14.16.2 Point of Care Infectious Disease Testing Assay Market and Technology

Trends 164

4.14.16.2.1 Point of Care Infectious Disease Testing Assay Market Trends 164

4.14.16.2.2 Point of Care Infectious Disease Testing Assay Technology Trends 164

4.14.16.2.3 Point of Care Infectious disease Testing Assay Strategic

Recommendations 164

4.15 Infant Jaundice 164

4.16 Anthrax 165

4.17 Rupture of Fetal Membranes (ROM) 167

4.18 Food Pathogens 167

4.19 Typhoid 167

5. POCT: Reagents and Equipment 168

5.1 Blood Glucose Monitoring 168

5.1.1 LifeScan 169

5.1.2 Roche Accu-Chek 172

5.1.3 Abbott Diabetes Care 174

5.1.4 HemoCue 175

5.1.5 Stanbio/GDS Technology 175

5.1.6 Abaxis, Inc. 176

5.1.7 Arkray (Japan) 176

5.1.8 Accurex (India) 177

5.1.9 Home Diagnostics, Inc. 177

5.1.10 Nova Biomedical 177

5.1.11 Bayer 177

5.1.11.1 Hemoglobin A1c Measurements 179

5.1.12 Biosite (now part of Alere) 179

5.1.13 Siemens Healthcare Diagnostics 179

5.1.14 Infopia 179

5.1.15 Diasys 179

5.1.16 Quotient Dx 180

5.1.17 Cholestech (Acquired by Inverness Medical Innovations, now named Alere)

180

5.1.18 Bio-Rad 180

5.1.19 Axis-Shield 180

5.2 Blood Gas and Electrolytes 180

5.2.1 Roche Corporation 180

5.2.2 TechnoMedica 180

5.2.3 Siemens Healthcare Diagnostics 181

5.2.4 Instrumentation Laboratory 181

5.2.5 Nova Biomedical 182

5.2.6 Radiometer 182

5.2.7 Abbott Laboratories 182

5.2.8 Span Diagnostics 183

5.2.9 Nexus Dx Avoximeter Systems for Co-oximetry 183

5.2.10 ITC (Nexus Dx) 184

5.2.11 Alere 185

5.3 Rapid Coagulation Tests 185

5.3.1 POC Coagulation Instrument Description 189

5.3.1.1 Roche Diagnostics Corp. 190

5.3.1.2 Abbott Laboratories 191

5.3.1.3 International Technidyne Corporation 192

5.3.1.4 Medtronic 193

5.3.1.5 HemoSense (Inverness) 194

5.3.1.6 Helena Laboratories Point of Care 194

5.3.1.7 Sienco, Inc. 195

5.3.1.8 Accumetrics 196

5.3.1.9 Alere 196

5.3.2 Connectivity Issues 196

5.3.3 Cost Benefits 197

5.3.4 Quality Control Issues 197

5.3.5 Certification for Point of Care Coagulation Devices 198

5.4 Rapid Cardiac Markers 198

5.4.1 Biosite Diagnostics (Inverness, now called Alere) 198

5.4.2 Roche Diagnostics 199

5.4.3 Ani Biotech 200

5.4.4 Response Biomedical Corporation 201

5.4.5 Siemens Healthcare Diagnostics (f/k/a Bayer Healthcare Diagnostics,

Diagnostic Products Corporation, and Dade Behring) 202

5.4.6 Lab21 Ltd. 202

5.4.7 Abbott Laboratories 202

5.4.8 LifeSign (Princeton BioMediTech Corp.) 202

5.4.9 Mitsubishi Kagaku Iatron 202

5.4.10 Alpha Scientific 202

5.5 Rapid Drugs of Abuse 203

5.5.1 Biosite Diagnostics (Inverness, now called Alere) 204

5.5.2 Abbott Diagnostics 205

5.5.3 Roche Diagnostics 205

5.5.4 BioScan Screening Systems, Inc. 206

5.5.5 American Bio Medica Corp. 206

5.5.6 Phamatech, Inc. 210

5.5.7 First Check Medical 210

5.5.8 OraSure 211

5.5.9 Avitar, Inc. 211

5.5.10 Concateno 212

5.5.11 Pathtech 212

5.5.12 Alfa Scientific Designs, Inc. 212

5.5.13 TCPI, Inc. 213

5.5.14 Roche 213

5.5.15 Biophor Diagnostics 213

5.6 Rapid Pregnancy and Fertility Tests 213

5.7 Fecal Occult Blood 215

5.7.1 Helena Laboratories 216

5.7.2 Biomerica 216

5.7.3 Beckman Coulter 216

5.7.4 Worldwide Medical 216

5.7.5 Aerscher Diagnostics 217

5.7.6 Enterix 217

5.7.7 Medix Biochemica 217

5.7.8 Orion Diagnostica 218

5.8 Hemoglobin Testing 218

5.8.1 Wampole Laboratories 218

5.8.2 HemoCue, Inc. 218

5.8.3 Stanbio 218

5.9 Miscellaneous Rapid Tests 218

5.9.1 Triage C. difficile Panel 218

5.9.2 Ketoacids 219

5.9.3 Acetaminophen 219

5.9.4 Estriol 219

5.9.5 H. pylori 220

5.9.6 Vaginal Fluid pH and Vaginitis 222

5.9.7 Prostate-specific Antigen (PSA) 222

5.9.8 Bladder Cancer 223

5.9.9 Other Rapid Cancer Tests 226

5.9.10 Fetal Status (PROM) 227

5.9.11 Osteoporosis 227

5.9.12 Hemodynamic Monitoring 227

5.9.13 Heparin-induced Thrombocytopenia 227

5.10 HIV 228

5.10.1 Whole Blood, Serum or Plasma-based HIV Tests 230

5.10.1.1 Bio-Rad Laboratories 230

5.10.1.2 Orgenics (Inverness, now called Alere) 230

5.10.1.3 StatSure Diagnostic Systems 231

5.10.1.4 Trinity Biotech 231

5.10.1.5 Savyon Diagnostics 231

5.10.1.6 MedPharm 231

5.10.1.7 American Bio Medica Corp. 232

5.10.1.8 Chembio Diagnostics 232

5.10.1.9 OraSure Technologies 232

5.10.1.10 Inverness (Alere) 233

5.10.2 Saliva-based HIV Tests 233

5.10.2.1 OraSure Collection Device 234

5.10.2.2 SureStat 235

5.10.3 Urine-based HIV Tests 235

5.10.3.1 MedMira Laboratories, Inc. 235

5.10.3.2 Medical Services International, Inc. 236

5.10.3.3 Maxim Biomedical 236

5.10.3.4 Wampole Laboratories 237

5.11 Cholesterol 237

5.11.1 Cholestech (now a brand of Inverness Medical Innovations) 237

5.11.2 Actimed Laboratories 238

5.11.3 StatSite Meter 239

5.11.4 Polymer Technology Systems 239

5.11.5 PreMD, Inc. (f/k/a International Medical Innovations, Inc. [IMI]) 239

5.11.6 Abaxis, Inc. 239

5.12 Infectious Disease 240

5.12.1 C. difficile 240

5.12.2 Giardia 240

5.12.3 Dengue Fever 241

5.12.4 Malaria Testing 241

5.12.5 Rapid Influenza Testing 243

5.12.6 Streptococcus Testing 246

5.12.7 Chlamydia 248

5.12.8 Mononucleosis 248

5.12.9 Rubella 250

5.12.10 Staphylococcus aureus and MRSA 250

5.12.11 Hepatitis 251

5.12.12 E. Coli O157 253

5.12.13 Gonorrhea Testing 253

5.12.14 Smallpox 253

5.12.15 SARS 253

5.12.16 Rabies 254

5.12.17 Tuberculosis 254

5.12.18 Avian Flu 254

5.12.19 West Nile Virus 254

5.12.20 Herpes Simplex Virus Type-2 255

5.12.21 Legionella 255

5.12.22 RSV 255

5.13 Infant Jaundice 256

5.14 Anthrax 257

5.15 Homeland Defense (Plague and Tularemia) 259

5.16 BSE (Mad Cow Disease) 259

5.17 Tuberculosis 259

5.18 Typhoid 260

5.19 Avian Flu 260

5.20 Food Pathogens (Salmonella, Listeria, Campylobacter) 260

5.21 Ruptured Fetal Membranes (ROM) 261

6. POCT: Growth Regulators 263

6.1 Moderators of Growth 263

6.2 Personnel Acceptance 263

6.3 Key People for POCT 264

6.4 Information Management Issues 264

6.4.1 Elements of Information Management for POCT: Information Processing

Capabilities 266

6.4.2 Data Mining 266

6.4.3 Middleware 266

6.4.4 Web Portals 267

6.4.5 POCT-1A Standard 267

6.5 Key Elements for POCT 268

6.6 POCT and Reimbursement 268

6.7 Effectiveness of Clinical Outcomes 270

6.8 Rapid Near-Patient Testing in Hospitals 271

6.9 Satellite Facilities 271

6.10 Regionalization of Laboratory Care 272

6.11 Requirements for POCT 273

6.12 Locations of Point of Care for Patient Care 274

6.13 Benefits of POCT 274

6.14 Cost Elements of POCT 275

6.15 Necessary Functions in POCT 275

6.16 TAT for POCT 275

6.17 Clinical Laboratory Improvement Amendments (CLIA) 276

6.18 Sexually-transmitted Diseases in Underdeveloped Countries 277

7. Business Trends in the Point of Care Sector 279

7.1 Sector Consolidation 279

7.2 Diagnostic Testing Growth Trends 280

7.3 Acquisition, License Agreements, Internal Development and Partnerships 281

7.4 Product Testing Depth in POCT 284

7.5 Government Regulation 284

7.5.1 U.S. Regulation 285

7.5.1.1 Importing Medical Devices into the U.S. 286

7.5.1.2 Exporting Medical Devices from the U.S. 287

7.5.2 U.K. Regulation 287

7.5.3 E.U. Regulation 288

7.5.3.1 French Regulation 290

7.5.4 Japanese Regulation 290

7.5.5 Korean Regulation 291

7.6 Increased Market Penetration 291

7.7 Costs of doing Business in Europe 292

7.8 Drivers of European Diagnostics Testing 292

7.9 European Reimbursement Practices 292

7.10 Cost Containment in Europe 293

8. Technology Platform Innovations in POCT 296

8.1 Sensor Systems for Diagnostic Applications 296

8.2 Glucose Measurements 299

8.2.1 Continuous Glucose Monitoring Systems 301

8.3 Glucose Test Methods 303

8.4 Cholesterol Testing 304

8.5 The New Paradigm 304

8.6 Consolidated Workstations and Modularity 305

8.7 Automation and Robotics in the Clinical Laboratory 305

8.8 Laboratory Information Systems (LIS) 306

8.8.1 NOVIUS Lab 306

8.9 Biosensor Technology 306

8.10 Nanogen Third Generation Point of Care Analyzer 308

8.11 Quidel MChip 309

9. Data Management and Connectivity 310

9.1 Wireless LANs 310

9.2 Connectivity Platforms 313

9.2.1 DataLink Data Management System 313

9.2.2 RALS-Plus 314

9.2.2.1 International Technidyne Corporation HEMOCHRON Signature Elite 316

9.2.2.2 Siemens Diagnostics Rapidpoint Coag 316

9.2.2.3 Radiometer 316

9.2.2.4 HemoCue's DM Hemoglobin 316

9.2.2.5 Roche Diagnostics 316

9.2.3 BD.id 317

9.2.4 Medical Implant Communications Service (MICS) 317

9.3 Advantages of POCT Connectivity 317

9.3.1 Cost Benefit of POCT and IT Connectivity 318

9.3.2 Hospital Network Issues 318

10. Corporate Profiles 319

10.1 Abaxis, Inc. 319

10.2 Abbott Laboratories 322

10.3 Accumetrics, Inc. 324

10.4 AccuTech, LLC 324

10.5 ACON Laboratories 324

10.6 Acrongenomics 324

10.7 Aerscher Diagnostics 325

10.8 Akers Biosciences, Inc. 325

10.9 Alere 325

10.10 Alfa Scientific Designs, Inc. 328

10.11 American Bio Medica Corporation 328

10.12 Amic AB 329

10.13 Ani Biotech Oy Ltd. 329

10.14 Arkray, Inc. 330

10.15 Atonomics A/S 330

10.16 Audit Diagnostics 330

10.17 Augurix Diagnostics Ltd. 330

10.18 Axis-Shield 330

10.19 Bayer 331

10.20 Beckman Coulter 331

10.21 BioLytical Laboratories 333

10.22 Biomerica, Inc. 333

10.23 BiOracle 334

10.24 Bio-Rad Laboratories, Inc. 334

10.25 BioScan Screening Systems, Inc. 335

10.26 BioSite 335

10.27 Calmark Sweden AB 335

10.28 Calypte Biomedical Corporation 335

10.29 Chembio Diagnostic Systems 336

10.30 Chempaq A/S 336

10.31 Cholestech 336

10.32 Claros Diagnostics 336

10.33 Concateno Plc 336

10.34 Dexcom 337

10.35 Enigma Diagnostics Ltd. 337

10.36 Epinex Diagnostics 337

10.37 Eurotrol 338

10.38 Exalenz Bioscience 338

10.39 GenBio 338

10.40 Genzyme 338

10.41 Helena Laboratories 339

10.42 HemoCue AB 339

10.43 HemoSense 339

10.44 Home Diagnostics (Nipro Diagnostics) 339

10.45 IND Diagnostic 339

10.46 Instrumentation Laboratory Company 339

10.47 Jant Pharmacal Corporation 340

10.48 Johnson & Johnson 340

10.49 Lein Applied Diagnostics 341

10.50 LifeAssays AB 341

10.51 LifeSign 341

10.52 Mediwatch 341

10.53 Medix Biochemica 341

10.54 MedMira 341

10.55 MELA Sciences (formerly Electro-Optical Sciences) 342

10.56 Meretek Diagnostics Group 342

10.57 Meridian Bioscience 342

10.58 Micronics 343

10.59 3M 343

10.60 New Horizons Diagnostics 343

10.61 OraSure Technologies 343

10.62 Orion Diagnostica 344

10.63 Polymer Technology Systems 344

10.64 Prima Biomedical Company 344

10.65 QBC Diagnostics 345

10.66 Qualigen 345

10.67 Quidel 345

10.68 Radiometer Medical 348

10.69 Response Biomedical 348

10.70 SA Scientific 348

10.71 Siemens AG 349

10.72 Stanbio Laboratory 349

11. POCT Sector Trends and Forecasts 351

11.1 Home Care Analysis as Part of Near-Patient Testing 351

11.2 Non-Traditional Collection for POCT 351

11.3 New Systems for Critical Care and Near-Patient Testing 351

11.4 Utility of Near-Patient Testing in Critical Care Settings 352

11.5 Physician's Office Market 352

11.6 Information Management Advances 353

11.7 Test-Ordering Patterns and Demand for POCT 353

11.8 Demand for Emergency Department Services 353

11.9 Move Away from Central Laboratory 354

11.10 Healthcare Cost Controls 355

11.11 M&A in POCT 355

11.12 Competition for Services 356

11.13 Drivers of POCT 356

11.14 Confluence of New Technology 357

11.15 Difficulties of Design for Point of Care Products 357

11.16 European Hospital Structure 357

11.17 The Biggest New Opportunities in POCT 357

12. Corporate Directory 358

INDEX OF FIGURES

Figure 3.1: Blood Tests Ordered in Emergency Department Visits 26

Figure 3.2: Worldwide Distribution of IVD Testing, 2010 30

Figure 3.3: Global Point of Care Revenues, 2005-2012 32

Figure 3.4: Global Growth of Point of Care Testing Volume, 2000-2008 32

Figure 3.5: Global POCT Share of Total IVD Testing Market, 2010 34

Figure 4.1: Number of HbA1c Tests Performed Globally as POCT, 1991-2006 93

Figure 4.2: Percentage of Visits for Influenza-like Illness (ILI) Reported by

the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) and

Weekly National Summary, September 30, 2007-February 12, 2011 145

Figure 4.3: Influenza Positive Tests Reported to CDC by U.S. WHO/NREVSS

Collaborating Laboratories, National Summary, 2010-2011 146

Figure 5.1: Global POCT Share of HIV Testing Market, 2008 230

Figure 6.1: Annual Rate of Emergency Room Visits by Primary Expected Source of

Payment 270

INDEX OF TABLES

Table 2.1: Percentage of POCT Performed in Selected Hospitals 21

Table 2.2: POCT Procedural Advantages for Hospital Testing 23

Table 2.3: POCT Trends 24

Table 2.4: Professional POCT Compared to Home Testing 24

Table 2.5: Drivers for Integrating POCT into Hospital Routines 24

Table 3.1: Actual Reported Number of ER Visits in U.S. Hospitals, 1997-2010 25

Table 3.2: Number of Point of Care Tests in the U.S., 2000-2012 26

Table 3.3: Global Clinical Laboratory Market Sales, 1998-2011 28

Table 3.4: Overall IVD Testing Market Worldwide, 2010 29

Table 3.5: Worldwide Distribution of IVD Testing, 2010 29

Table 3.6: Top 12 Country IVD Testing Markets, 2010 30

Table 3.7: Global Point of Care Revenues, 2005-2012 31

Table 3.8: Worldwide POCT Market Size by Geographic Location, 2005-2012 33

Table 3.9: Worldwide Distribution of POCT, 2010 33

Table 3.10: Worldwide Clinical Diagnostic POCT and Rapid Test Market Segments,

2010 33

Table 3.11: Worldwide POCT by Performance Location, 2010 34

Table 3.12: Largest POCT Diagnostic Companies Worldwide, 2010 34

Table 3.13: U.S. Clinical Laboratory Testing Market, 2003-2012 35

Table 3.14: U.S. Clinical Laboratory Diagnostic Test Market Segments by Location

of Analysis, 2010 35

Table 3.15: U.S. POCT Market, 2000-2012 36

Table 3.16: U.S. POCT by Performance Location, 2010 36

Table 3.17: U.S. Clinical Diagnostic POCT and Rapid Test Market Segments, 2010

36

Table 3.18: European Clinical Laboratory Testing IVD Reagents and Instruments

Market in

Dollars, 2000-2012 37

Table 3.19: European Clinical Laboratory Testing IVD Reagents and Instruments

Market in

Euros, 2000-2012 37

Table 3.20: European Clinical Laboratory Testing Diagnostics by Country Market

Estimates, 2010 38

Table 3.21: European Rapid POCT by Country Market Estimates, 2010 39

Table 3.22: Regional Comparison of Healthcare Spending for IVD for Eastern

Europe 42

Table 3.23: European POCT Market, 2005-2012 42

Table 3.24: Top 12 POCT Country Markets, 2010 42

Table 3.25: German Clinical Laboratory Testing Diagnostics Products Market

Sales, 2003-2012 43

Table 3.26: German POCT Diagnostics Products Market Sales, 2003-2012 43

Table 3.27: German Clinical Diagnostic Rapid Test Market Segments, 2010 44

Table 3.28: U.K. Clinical Laboratory Diagnostics Products Market Sales,

2003-2012 45

Table 3.29: U.K. POCT Diagnostics Products Market Sales, 2006-2012 46

Table 3.30: U.K. Clinical Diagnostic Rapid Test Market Segments, 2010 46

Table 3.31: Major U.K. IVD Manufacturers 47

Table 3.32: U.S. IVD Manufacturers Doing Business in the U.K. 47

Table 3.33: Other European Companies that Manufacture IVD Products in the U.K.

47

Table 3.34: French Clinical IVD Testing Diagnostics Products Market Sales,

2003-2012 48

Table 3.35: French POCT Diagnostics Products Market Sales, 2005-2012 49

Table 3.36: French Clinical Diagnostic Rapid Test Market Segments, 2010 49

Table 3.37: Italian Laboratory Diagnostics Products Market Sales, 2003-2012 50

Table 3.38: Italian POCT Diagnostics Products Market Sales, 2005-2012 50

Table 3.39: Italian Clinical Diagnostic Rapid Test Market Segments, 2010 50

Table 3.40: Spanish Clinical Laboratory Diagnostics Products Market Sales,

2003-2012 51

Table 3.41: Spanish Clinical Diagnostic Rapid Test Market Segments, 2010 52

Table 3.42: Spanish POCT Diagnostics Products Market Sales, 2005-2012 52

Table 3.43: Scandinavian POCT Diagnostics Products Market Sales, 2000-2012 53

Table 3.44: Swedish Clinical Laboratory Diagnostics Products Market Sales,

2003-2012 53

Table 3.45: Swedish POCT Diagnostics Products Market Sales, 2005-2012 54

Table 3.46: Finnish Clinical Laboratory Diagnostics Products Market Sales,

2003-2012 54

Table 3.47: Finnish POCT Diagnostics Products Market Sales, 2005-2012 55

Table 3.48: Norwegian Clinical Laboratory Diagnostics Products Market Sales,

2003-2012 55

Table 3.49: Norwegian POCT Diagnostics Products Market Sales, 2005-2012 56

Table 3.50: Swiss Clinical Laboratory Diagnostics Products Market Sales,

2003-2012 56

Table 3.51: Swiss POCT Diagnostics Products Market Sales, 2005-2012 57

Table 3.52: Dutch Clinical Laboratory Diagnostics Products Market Sales,

2003-2012 57

Table 3.53: Dutch POCT Diagnostics Products Market Sales, 2005-2012 58

Table 3.54: Belgian Clinical Laboratory Diagnostics Products Market Sales,

2003-2012 58

Table 3.55: Belgian POCT Diagnostics Products Market Sales, 2005-2012 59

Table 3.56: Portuguese Clinical Laboratory Diagnostics Products Market Sales,

2003-2012 59

Table 3.57: Portuguese POCT Diagnostics Products Market Sales, 2005-2012 60

Table 3.58: Austrian Clinical Laboratory Diagnostics Products Market Sales,

2003-2012 60

Table 3.59: Austrian POCT Diagnostics Products Market Sales, 2005-2012 61

Table 3.60: Greek Clinical Laboratory Diagnostics Products Market Sales,

2003-2012 61

Table 3.61: Greek POCT Diagnostics Products Market Sales, 2005-2012 62

Table 3.62: Polish Clinical Laboratory Diagnostics Products Market Sales,

2003-2012 62

Table 3.63: Polish POCT Diagnostics Products Market Sales, 2005-2012 63

Table 3.64: Czech Clinical Laboratory Diagnostics Products Market Sales,

2004-2012 63

Table 3.65: Czech POCT Diagnostics Products Market Sales, 2005-2012 64

Table 3.66: Turkish POCT Market, 2000-2012 64

Table 3.67: Japanese POCT Market, 2000-2012 65

Table 3.68: Japanese Population and Aging Demographics Forecast, 2000-2050 65

Table 3.69: Indian IVD Market for Instruments and Reagents, 2004-2012 66

Table 3.70: Number of Automated Clinical Labs in India, 2004-2012 67

Table 3.71: Indian IVD Market, 2010 67

Table 3.72: Indian POCT Diagnostics Products Market Sales, 2000-2012 71

Table 3.73: Chinese IVD Market, 2006-2012 72

Table 3.74: Number of Automated Clinical Labs in China, 2004-2012 73

Table 3.75: Chinese IVD Market, 2010 73

Table 3.76: Chinese POCT Diagnostics Products Market Sales, 2000-2012 79

Table 3.77: Rest of the World POCT Market, 2000-2012 81

Table 3.78: Canadian POCT Market, 2000-2012 82

Table 3.79: Brazilian POCT Market, 2000-2012 82

Table 3.80: Australian POCT Market, 2000-2012 83

Table 4.1: World Market Share of Point of Care Glucose Monitoring Marketers 88

Table 4.2: Global Population of Persons with Diabetes, 1995 and 2025 89

Table 4.3: Professional Glucose Testing Market for POCT Worldwide Revenue and

Forecasts, 2001-2012 90

Table 4.4: U.S. Point of Care Glucose Testing Market, 1997-2012 90

Table 4.5: Rapid Testing U.S. Market Share for Blood Glucose Testing Segment 92

Table 4.6: HbA1c Testing Market for POCT Worldwide, 2006-2012 93

Table 4.7: Point of Care Glucose Testing Market: Market Drivers Ranked in Order

of Impact 94

Table 4.8: Point of Care Glucose Testing Market: Market Restraints Ranked in

Order of Impact 94

Table 4.9: SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and

Threats of the Glucose Point of Care Market 96

Table 4.10: Critical Care Blood Gas Testing Market for POCT Worldwide, 2006-2012

97

Table 4.11: Blood Gas and Electrolyte Market for POCT in the U.S., 2001-2012 97

Table 4.12: Location Market Share of Critical Care Blood Gas Testing, 1990 and

2010 97

Table 4.13: Manufacturer Market Share U.S. POCT Blood Gas and Electrolytes

Market, 2010 99

Table 4.14: Hospital Locations of Point of Care Coagulation Testing 100

Table 4.15: Drivers for Point of Care Coagulation Testing 101

Table 4.16: Barriers for Point of Care Coagulation Testing 101

Table 4.17: Coagulation Testing Market for POCT Worldwide, 2006-2012 102

Table 4.18: Handheld Coagulation Testing Market for POCT Worldwide, 2006-2012

102

Table 4.19: Coagulation Market for POCT in the U.S., 2001-2015 103

Table 4.20: Point of Care Prothrombin Market for POCT in the U.S., 2000-2010 104

Table 4.21: SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and

Threats of the Coagulation Point of Care Market 108

Table 4.22: Cardiac Marker Market for POCT in the U.S., 2001-2016 110

Table 4.23: Cardiac Marker Market for POCT Worldwide, 2001-2016 111

Table 4.24: Manufacturer Market Share U.S. POCT Cardiac Marker Market, 2010 111

Table 4.25: Cardiac Marker Market for POCT in Europe, 2008-2016 112

Table 4.26: Point of Care Cardiac Marker Testing Market: Market Drivers Ranked

in Order of Impact 113

Table 4.27: Point of Care Cardiac Marker Testing Market: Market Restraints

Ranked in Order of Impact 113

Table 4.28: SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and

Threats of the Cardiac Marker Point of Care Market 114

Table 4.29: Drugs of Abuse Testing Market for POCT Worldwide, 2006-2015 119

Table 4.30: U.S. Point of Care Drugs of Abuse Testing Market, 2006-2015 120

Table 4.31: Drug Testing Needs Tier I for Rapid Serum POCT in the Emergency

Department 121

Table 4.32: Stat Urine Testing Drug Recommendations 121

Table 4.33: Device Specifications for POCT Breath Alcohol Analysis 124

Table 4.34: Global Point of Care Urine Test Strip Testing Market, 2001-2010 124

Table 4.35: Global Point of Care Urine Test Strip POCT Testing Market, 2006-2012

125

Table 4.36: U.S. Point of Care Urine Test Strip Testing Market, 2001-2011 125

Table 4.37: U.S. Point of Care Urine Test Strip Testing Market Share 125

Table 4.38: Medicare Fee Schedule for Urine Chemistry Testing, 127

Table 4.39: Pregnancy Testing Market for POCT Worldwide, 2006-2012 128

Table 4.40: U.S. Point of Care Pregnancy Testing Market, 2001-2012 128

Table 4.41: U.S. Market Share for Rapid Point of Care Pregnancy Tests 128

Table 4.42: Hemoglobin Testing Market for POCT Worldwide, 2006-2012 129

Table 4.43: Drivers of Demand for HIV Testing 134

Table 4.44: Worldwide POCT Market for HIV, 2001-2012 135

Table 4.45: U.S. POCT Market for HIV, 2001-2012 135

Table 4.46: Countries with the Highest Prevalence of HIV/AIDS 137

Table 4.47: FDA-approved Rapid HIV Antibody Screening Tests 138

Table 4.48: Cholesterol Testing Market for POCT Worldwide, 2006-2012 140

Table 4.49: Infectious Disease Testing Market for POCT Worldwide, 2006-2012 141

Table 4.50: Worldwide Point of Care Influenza Testing Market, 2002-2010 147

Table 4.51: U.S. Point of Care Influenza Testing Market, 2002-2010 147

Table 4.52: U.S. Market Share for Rapid Point of Care Influenza Tests, 2010 148

Table 4.53: Worldwide Point of Care Strep A Testing Market, 2002-2010 148

Table 4.54: U.S. Point of Care Strep A Testing Market, 2002-2010 149

Table 4.55: U.S. Market Share for Rapid Point of Care for Group A Strep Tests

149

Table 4.56: Global Market for Chlamydia Diagnostic Testing, 2000-2010 150

Table 4.57: U.S. Market for Chlamydia Diagnostic Testing, 2000-2010 150

Table 4.58: U.S. Market for MRSA Rapid Testing, 2006-2013 155

Table 4.59: Global Market for Gonorrhea Diagnostic Testing, 2000-2010 158

Table 4.60: Global Market for TB Diagnostic Testing, 2000-2010 160

Table 4.61: Point of Care Infectious Disease Testing Market: Market Drivers

Ranked in Order of Impact 163

Table 4.6

To order this report:

: Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 2016 In a historic vote among its members this weekend, ... medical cannabis cultivation facility and dispensary on tribal land near ... as a provider for patients in the state,s Medical Cannabis Program. ... a provider for patients in the state,s Medical Cannabis Program. ... the project and pursue designation from the State of New ...
(Date:2/8/2016)... 2016 http://www.researchandmarkets.com/research/x6mkjm/knee ) has ... Devices Market by Product Type (Primary (Cemented & ... Canada, Eu-5, Japan, Bric, Turkey, Indonesia - Global ... their offering. --> http://www.researchandmarkets.com/research/x6mkjm/knee ) ... Reconstruction Devices Market by Product Type (Primary (Cemented ...
(Date:2/8/2016)... ARBOR, Mich. , Feb. 8, 2016  The ... Arbor announced today that, as part of ... become one of the first hospitals in the U.S. ... Karin Muraszko , M.D., U-M,s chair of neurosurgery. ... chair of neurosurgery. --> The BrightMatter ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... ... executive networking and relationship-marketing firm, announced today that nominations will be accepted ... Executive® (ISE®) West Awards. , Awards include the Information Security Executive® ...
(Date:2/8/2016)... ... 2016 , ... GrassrootsHealth published data from its D*action public ... in the GrassrootsHealth cohort with substantially higher vitamin D levels than a cohort ... states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits of vitamin ...
(Date:2/8/2016)... ... , ... The schedule is now online for the largest and ... is being held May 25-29 at the Loews Chicago O’Hare Hotel, continues to give ... of chronic illness in children. , Very recent articles have cited 1 child in ...
(Date:2/7/2016)... AZ (PRWEB) , ... February 07, 2016 , ... ... Neck and Facial Plastics, has added Kybella® to his medical and surgical expertise. ... a newly approved FDA injectable medication used as a non-surgical alternative for reduction ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... eating disorder treatment helps to reduce the frequency and level of relapse. ... Phase: Re-Establishing Healthy Identity and Purpose,” will explore the critical tasks of the ...
Breaking Medicine News(10 mins):